A recent systematic review and meta-analysis published in 2026 reveals that metabolic and bariatric surgery (MBS) offers significantly better cardiovascular protection than glucagon-like peptide-1 (GLP-1) receptor agonists for individuals battling obesity and type 2 diabetes. The study indicates that MBS is notably more effective in reducing both major adverse cardiovascular events (MACE) and all-cause mortality.
As effective interventions, both MBS and GLP-1 receptor agonists are commonly utilized to manage obesity and type 2 diabetes. While GLP-1 receptor agonists have established themselves as a valuable treatment choice that improves metabolic health and decreases cardiovascular mortality, MBS has shown remarkable efficacy, achieving diabetes remission in approximately 31% to 56% of patients.
The review assessed nearly 20,000 individuals with obesity and type 2 diabetes, comparing the impact of MBS versus GLP-1 receptor agonist therapy on all-cause mortality and nonfatal MACE. The findings revealed that MBS significantly lowered the risk for these outcomes, boasting a relative risk reduction of 52% compared to the drug therapy. Furthermore, MBS was linked to greater sustained weight loss than its pharmacological counterpart.
Significantly, the benefits of MBS extend beyond mere weight loss and blood sugar control. Researchers suggested that surgery’s multifaceted effects on metabolic health and cardiovascular risk contribute to its superior outcomes. The analysis highlighted that MBS provides a more pronounced and enduring reduction in risks, particularly for patients with a long history of diabetes and those at higher cardiovascular risk.
Although GLP-1 receptor agonists effectively mitigate cardiovascular events and improve metabolic markers, the study emphasizes that the long-term patient benefits are notably greater with surgical intervention. However, it is crucial to recognize the role of GLP-1 receptor agonist therapy, which remains vital for patients who are not candidates for surgery or who prefer to pursue non-surgical options.
The compelling evidence from recent meta-analyses and large-scale cohort studies underscores the advantages of MBS over GLP-1 receptor agonists in terms of reducing MACE and all-cause mortality in the population with obesity and type 2 diabetes.
In sum, as healthcare continues to evolve, these findings may influence treatment protocols, ensuring that both clinicians and patients are aware of the significant cardiovascular benefits offered by metabolic and bariatric surgery.
Original Source: https://www.emjreviews.com/diabetes/news/weight-loss-surgery-healthier-for-the-heart-than-glp-1s/
Category :
Tags:
Publish Date: 2026-02-24 19:33:00
